Showing results (31-40 of 104) with videos related to
Sort By:
Pageof 11
The Journal of Clinical Investigation|March 14, 2024
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionKyle Vaccaro, Juliet Allen, Troy W Whitfield, et al.Molecular Cancer Therapeutics|January 21, 2025
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer ModelsShan Lu, Xiao Pan, Eva Volckova, et al.Cell Reports|June 20, 2019
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor SensitivityLynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal MetastasesHironori Uruga, Emine Bozkurtlar, Tiffany G Huynh, et al.Scientific Reports|February 12, 2021
Targeting the DNA replication stress phenotype of KRAS mutant cancer cellsTara Al Zubaidi, O H Fiete Gehrisch, Marie-Michelle Genois, et al.Molecular Cell|April 30, 2024
Unprocessed genomic uracil as a source of DNA replication stress in cancer cellsSneha Saxena, Christopher S Nabel, Turner W Seay, et al.Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2016
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune MicroenvironmentTiffany G Huynh, Vicente Morales-Oyarvide, Meghan J Campo, et al.The Journal of Clinical Investigation|June 29, 2023
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancerFrancesca Nardi, Naiara Perurena, Amy E Schade, et al.Nature Communications|October 2, 2022
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimeticsCameron S Fraser, Johan K E Spetz, Xingping Qin, et al.Pageof 11